BIR repeat-containing ubiquitin conjugating enzyme (BRUCE) regulation of β-catenin signaling in the progression of drug-induced hepatic fibrosis and carcinogenesis
Chrystelle L Vilfranc, Li-Xiao Che, Krushna C Patra, Chun-Ying Du, Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, United States
Liang Niu, Department of Environmental and Public Health Sciences, University of Cincinnati, Cincinnati, OH 45267, United States
Olugbenga Olowokure, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, United States
Jiang Wang, Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45267, United States
Shimul A Shah, Department of Surgery, University of Cincinnati, Cincinnati, OH 45267, United States
Author contributions: Vilfranc CL, Che LX, Shah SA and Du CY performed study concept and design; Vilfranc CL and Che LX performed acquisition of data, analysis and interpretation of data; Vilfranc CL performed drafting of the manuscript, revision of the manuscript with important intellectual contribution; Che LX performed RNA-seq transcriptome analysis and edited the manuscript; Patra KC performed intellectual contribution, technical and material support, analysis and interpretation of data; Niu L support with RNA-seq analysis; Olowokure O performed study concept, intellectual contribution; Wang J performed intellectual contribution, histopathological design, analysis and interpretation of clinical data; Shah SA performed intellectual contribution, mentorship to CLV; Du CY performed critical revision of the manuscript, obtained funding, study supervision and manuscript revisions.
Supported by NIH (Du CY), No. R21CA241025-01; NIH (Du CY), No. RO1CA158323; NCI RO1 Diversity Supplement (Du CY), No. R01CA158323-05S; National Center for Advancing Translational Sciences of the National Institutes of Health (Du CY), No. 2UL1TR001425-05A1; University of Cincinnati Center for Environmental Genetics-NIH/NIEHS Award (Du CY), No. P30 ES006096; Pathways to Cancer Therapeutics T32 (Du CY and Vilfranc CL), No. CA117846-12.
Institutional animal care and use committee statement: All animal experiments were performed in accordance with guidelines approved by our Institutional Animal Care and Use Committee.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Ying Du, PhD, Associate Professor, Department of Cancer Biology, University of Cincinnati, 3125 Eden Avenue Room # 3216, Cincinnati, OH 45267, United States. email@example.com
Received: December 12, 2020
Peer-review started: December 12, 2020
First decision: January 7, 2021
Revised: January 15, 2021
Accepted: March 8, 2021
Article in press: March 8, 2021
Published online: March 27, 2021